Posted Apr. 13, 2010 at 10:13 a.m.

Premium Lock Local Tech Briefs: Cisco reports tandberg is finally a done deal; Novartis shows positive trial data for MS treatment; New chief for Novozymes' Va. unit

Published: 2010-04-13 10:13:41
Updated: 2010-04-13 10:13:41

Print this blog post

Local Tech Wire

A roundup of the latest high-tech and life science news from regional firms:

  • Cisco gets final Euro blessing for Tandberg deal

RESEARCH TRIANGLE PARK, N.C. — Cisco Systems says it has received final European Commission approval for its acquisition of Tandberg, The Wall Street Journal reported. The deal now must close in two weeks, the report stated.

The European Commission last month had approved the deal provided that Cisco make some concessions, and the U.S. Justice Department said it would not challenge the acquisition in view of Cisco's commitments to the EC.

Cisco, which employs more than 4,000 people at its campus in Research Triangle park, N.C., said it had agreed to enhance interoperability between its multi-screen video conferencing products and competitive products. It also agreed to appoint an independent monitor, who must be approved by the EC, to oversee the implementation of these commitments.

  • Novartis posts positive trial data for its MS drug

RESEARCH TRIANGLE PARK, N.C. — Novartis said Tuesday that newly disclosed trial data shows its Gilenia multiple-sclerosis treatment is effective for relapsing forms of the disease.

Data from the two-year FREEDOMS study showed that Gilenia 0.5 mg reduced annual relapse rates by 62 percent for treatment-naïve patients compared with placebo. For patients previously receiving other treatments, the annual relapse rates were reduced by 44 percent, Novartis said.

Novartis reported the results at the American Academy of Neurology annual meeting in Toronto.

  • New chief named for Novozymes' unit in Va.

ROANOKE, Va. — Denmark-based Novozymes has named a new chief for Novozymes Biologicals subsidiary in Roanoke County and Salem, the Roanoke Times reported Tuesday.

Patrick Patterson, 45, replaces Ted Melnik, 52, who has been Novozymes Biologicals president since its incorporation in July 2001.

The company and Melnik said his decision to leave was voluntary. He will stay with the company until the end of April. Patterson became president Monday. Melnik said he plans to "take a good sabbatical and then start to look for some other opportunities."

 

 

...Copyright 2013 WRAL Tech Wire. All rights reserved.

Please log in or register to view WRALTechWire Insider content


To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.

 1 Year Membership - 49.99 per year. Includes FREE unlimited access to online content, archives and discounts from Insider Partners. For less than $1 a week receive more than $900 in value.

 Monthly Membership - 4.99 per month. Includes FREE unlimited access every 30 days to online content only.

 Day Pass - 0.99 per day. Includes FREE unlimited access for 24 hours to online content only.

Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Jim Roberts
Entrepreneurship
Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll